Biological characteristics of intratumoral [F-18]-fluoromisonidazole distributionin a rodent model of glioma

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 823-830

  Hatano, Toshiyuki ^a,b   Zhao, Songji ^c   Zhao, Yan ^c   Nishijima, Ken Ichi ^c   Kuno, Norihito ^b   Hanzawa, Hiroko ^b   Sakamoto, Takeshi ^b   Tamaki, Nagara ^c   Kuge, Yuji ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HITACHI LTD   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

F 18 fluoromisonidazole; Cellular proliferation; Glucose metabolism; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE C 14; GLUCOSE TRANSPORTER 1; HYPOXYPROBE 1; KI 67 ANTIGEN; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER TISSUE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; GLIOMA; GLUCOSE METABOLISM; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; TUMOR GROWTH;

ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CELL HYPOXIA; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; GLIOMA; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HYPOXIA-INDUCIBLE FACTOR 1; KI-67 ANTIGEN; MALE; MISONIDAZOLE; NITROIMIDAZOLES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84873619404     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1781     Document Type: Article

References (42)

1. Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998. (Pubitemid 28193601)
2. Gray LH, Conger AD, Ebert M, Hornsey S and Scott OC: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648, 1953.
3. Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
4. Evans SM, Jenkins KW, Chen HI, Jenkins WT, Judy KD, Hwang WT, Lustig RA, Judkins AR, Grady MS, Hahn SM and Koch CJ: The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: A pilot study. Transl Oncol 3: 160-169, 2010.
5. Evans SM, Hahn SM, Magarelli DP and Koch CJ: Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 24: 467-472, 2001. (Pubitemid 32959104)
6. Troost EG, Laverman P, Philippens ME, et al: Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 35: 1803-1811, 2008.
7. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, van der Kogel AJ, Boerman OC and Bussink J: Imaging hypoxia after oxygenation- modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 80: 157-164, 2006. (Pubitemid 44314018)
8. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL and Krohn KA: Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14: 2623-2630, 2008.
9. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ and Bares R: Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46: 253-260, 2005. (Pubitemid 43073432)
10. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR and Krohn KA: Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12: 5435-5441, 2006. (Pubitemid 44497258)
11. Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6: 509-518, 1994.
12. Overgaard J and Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6: 10-21, 1996. (Pubitemid 26029371)
13. Moeller BJ and Dewhirst MW: HIF-1 and tumour radiosensitivity. Br J Cancer 95: 1-5, 2006. (Pubitemid 43980546)
14. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY and Dewhirst MW: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8: 99-110, 2005. (Pubitemid 41132739)
15. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999. (Pubitemid 29346576)
16. Kamlah F, Eul BG, Li S, Lang N, Marsh LM, Seeger W, Grimminger F, Rose F and Hänze J: Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 16: 195-205, 2009.
17. Le QT and Courter D: Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 27: 351-362, 2008.
18. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F and Beger HG: Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38: 1344-1348, 1997.
19. Aloj L, Caracó C, Jagoda E, Eckelman WC and Neumann RD: Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59: 4709-4714, 1999. (Pubitemid 29428980)
20. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003. (Pubitemid 37328811)
21. Zhao S, Kuge Y, Yi M, Zhao Y, Hatano T, Magota K, Nishijima K, Kohanawa M and Tamaki N: Dynamic 11C-methionine PET analysis has an additional value for differentiating tumors from granulomas: An experimental study using small animal PET. Eur J Nucl Med Mol Imaging 38: 1876-1886, 2011.
22. Tang G, Wang M, Tang X, Gan M and Luo L: Fully automated one-pot synthesis of [18F]fluoromisonidazole. Nucl Med Biol 32: 553-558, 2005. (Pubitemid 40854106)
23. Oh SJ, Chi DY, Mosdzianowski C, Kim JY, Gil HS, Kang SH, Ryu JS and Moon DH: Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module. Nucl Med Biol 32: 899-905, 2005. (Pubitemid 41505324)
24. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP and Wahl RL: Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 36: 1854-1861, 1995.
25. Toyama H, Ichise M, Liow JS, Modell KJ, Vines DC, Esaki T, Cook M, Seidel J, Sokoloff L, Green MV and Innis RB: Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography. J Nucl Med 45: 1398-1405, 2004. (Pubitemid 47618541)
26. Hatanaka Y, Imaoka Y, Torisu K, Kamihara Y, Hashizume K, Ichimura K, Yoshino T and Tani Y: A simplified, sensitive immunohistochemical detection system employing signal amplification based on fluorescyl-tyramide/ antifluorescein antibody reaction: its application to pathologic testing and research. Appl Immunohistochem Mol Morphol 16: 87-93, 2008.
27. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, Dannenberg C, Tannapfel A, Kluge R and Sabri O: [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30: 317-326, 2003. (Pubitemid 36556247)
28. Buatti J, Ryken TC, Smith MC, Sneed P, Suh JH, Mehta M and Olson JJ: Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol 89: 313-337, 2008.
29. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA and van der Kogel AJ: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62: 7066-7074, 2002. (Pubitemid 35424102)
30. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I and West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928-934, 2001. (Pubitemid 32708731)
31. Thorwarth D, Eschmann SM, Holzner F, Paulsen F and Alber M: Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80: 151-156, 2006. (Pubitemid 44301544)
32. Wyss MT, Honer M, Schubiger PA and Ametamey SM: NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 33: 311-318, 2006.
33. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U and Reinartz P: FDG - a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33: 1426-1431, 2006. (Pubitemid 44885408)
34. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, Stanzel S, Asadpour B, Demirel C, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E and Eble MJ: pO2 polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 7: 113, 2007.
35. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG and Krohn KA: Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10: 2245-2252, 2004. (Pubitemid 38445681)
36. Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saunder TH, O'Keefe GJ and Scott AM: Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 47: 1921-1926, 2006. (Pubitemid 47544979)
37. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S and Pruschy M: Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 12: 3518-3524, 2006.
38. Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ and Kaanders JH: Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncol 44: 335-344, 2008. (Pubitemid 351380978)
39. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF and Krohn KA: [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30: 695-704, 2003. (Pubitemid 36612952)
40. Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, Sato K, Fukuda H and Ido T: Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 26: 750-757, 1999. (Pubitemid 29338663)
41. Dewhirst MW: Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res 67: 854-855, 2007.
42. Søvik A, Malinen E and Olsen DR: Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 73: 650-658, 2009.